Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

Next Previous
X
Search
Trial Profile

An Open Label, Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vididencel (Primary)
  • Indications Ovarian cancer
  • Focus Pharmacodynamics
  • Acronyms ALISON

    • Most Recent Events

    • 22 Dec 2023 Status changed from recruiting to active, no longer recruiting, according to a Mendus media release.
    • 22 Dec 2023 According to a Mendus media release, this trial is fully recruited with 17 patients. Mendus expects further read outs of the trial in 2024, including a survival analysis in 2024H2.
    • 28 Sep 2023 According to an Immunicum media release, data from the ongoing Phase 1 ALISON trial in ovarian cancer will be presented at the 38th Society for the Immunotherapy of Cancer meeting (SITC 2023),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top